| Treatment of mild to moderate facial melasma with the lumixyl topical brightening system. | |
| | |
MedLine Citation:
|
PMID: 22527440 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Background: Melasma is a cutaneous disorder associated with an overproduction of melanin by the tyrosinase enzyme. A proprietary oligopeptide (LumixylTM) was previously shown to competitively inhibit mushroom and human tyrosinase in vitro without the associated cytotoxicity of hydroquinone and to diminish the appearance of facial melasma. Objective: The aim of this case study was to determine if the Lumixyl Topical Brightening System (0.01% oligopeptide cream, an antioxidant cleanser, 20% glycolic acid lotion and physical sunscreen) accelerates clearance of mild-to-moderate melasma. Results: All patients showed improvement in their facial melasma with 1 of 4 patients showing complete clearance after just 6 weeks. Conclusions: Results suggest that this regimen may be a useful new tool to treat mild to moderate melasma. J Drugs Dermatol. 2012;11(5):660-662. |
| | |
Authors:
|
Basil M Hantash; Felipe Jimenez |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of drugs in dermatology : JDD Volume: 11 ISSN: 1545-9616 ISO Abbreviation: J Drugs Dermatol Publication Date: 2012 May |
Date Detail:
|
Created Date: 2012-04-24 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101160020 Medline TA: J Drugs Dermatol Country: United States |
Other Details:
|
Languages: eng Pagination: 660-2 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Infliximab (remicade) and increased incidence of development of Basal cell carcinoma.
Next Document: Pretreatment with anti-flagellin serum delays acute lung injury in rats with sepsis.